13F Holdings
中文EN

ORGO Organogenesis Holdings Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661181 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-24.3%
TTM net income YoY-13,567.9%
TTM EPS YoY-1,400.0%
Revenue 3-yr CAGR-7.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-24.5%
Net margin-38.4%
FCF margin-0.0%
EBITDA margin-20.0%

Returns

ROE-72.2%
ROA-30.8%
ROIC (approx.)-47.0%
Asset turnover0.80x

Leverage & solvency

Liabilities / assets28.8%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.08x
Accruals ratio-33.2%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$564.17M$482.04M$433.14M$450.89M$467.36M
Cost of revenue—$115.74M$106.48M$105.02M$114.20M
Gross profit—$366.30M$326.66M$345.87M$353.16M
R&D expense$44.54M$50.27M$44.38M$39.76M$30.74M
SG&A expense$326.24M$294.51M$269.75M$283.81M$250.20M
Operating income$44.69M-$1.28M$12.53M$22.30M$72.22M
Interest expense-$2.28M$1.54M$2.19M$2.01M$7.24M
Pretax income$46.97M-$2.81M$10.39M$20.28M$63.09M
Income tax$9.94M-$3.67M$5.45M$4.75M-$31.12M
Net income$37.03M$861,000$4.95M$15.53M$94.20M
EBITDA$59.97M$12.34M$22.97M$28.15M$78.00M
EPS (basic)0.16-0.010.040.120.73
EPS (diluted)0.15-0.010.040.120.70
Weighted avg. shares (diluted)130.25M131.67M132.75M132.38M133.66M
Balance sheet
Cash & equivalents$93.68M$136.15M$104.34M$103.29M$114.53M
Receivables$217.45M$109.86M$82.00M$89.45M$82.46M
Inventory$29.63M$26.22M$28.25M$24.78M$25.02M
Current assets$362.19M$285.94M$225.04M$222.61M$226.98M
PP&E, net$103.71M$89.13M$116.23M$102.46M$79.16M
Goodwill$28.77M$28.77M$28.77M$28.77M$28.77M
Intangibles$9.14M$12.47M$15.87M$20.79M$25.67M
Total assets$598.73M$497.89M$460.02M$449.36M$443.26M
Current liabilities$100.12M$77.48M$80.51M$75.02M$82.70M
Long-term debt——$66.56M$71.25M$74.06M
Total debt——$66.56M$71.25M$74.06M
Total liabilities$164.81M$112.57M$181.36M$183.69M$201.92M
Shareholders' equity$300.13M$262.90M$278.66M$265.67M$241.34M
Net debt——-$37.77M-$32.04M-$40.47M
Shares outstanding126.95M125.73M131.32M130.92M128.68M
Cash flow statement
Operating cash flow-$10.31M$14.21M$30.92M$24.86M$61.98M
Capital expenditure$14.15M$10.03M$24.36M$33.90M$31.22M
Free cash flow-$24.46M$4.18M$6.55M-$9.04M$30.76M
Investing cash flow-$14.15M-$10.03M-$24.36M-$33.90M-$31.22M
Financing cash flow-$17.36M$27.64M-$5.50M-$2.20M-$1.04M
Depreciation & amortization$15.27M$13.62M$10.45M$5.84M$5.78M
Stock-based compensation$13.30M$10.58M$9.00M$6.55M$3.86M
Share buybacks—$25.48M$0$0—

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.